ERBB Alteration Linked to Improved PFS With Afatinib in Urothelial Cancer
May 5th 2016Five of 6 patients with metastatic urothelial cancer and at least 1 of 2 genetic alterations demonstrated a marked improvement in 3-month progression free survival of 6.6 months when given afatinib (Gilotrif), compared with patients who lacked these specific genetic abnormalities.